APLIFAppili Therapeutics Inc.

About Appili Therapeutics Inc. (APLIF)

Appili Therapeutics Inc. (APLIF) is a Biotechnology company headquartered in Halifax, NS, Canada whose shares trade over-the-counter on the Pink tier.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

Products and services

Appili is a pharmaceutical company focused on the acquisition and development of novel medicines targeting unmet needs in infectious disease.

APLIF key facts

Ticker symbol

APLIF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Halifax, NS, Canada

Country of incorporation

CA

Year of incorporation

2015

Employees

9

Estimated market cap

$3.02M (as of May 8, 2025)

Shares outstanding

121,266,120

Reporting standard

International Reporting: Toronto Stock Exchange

Audit status

Audited

Fiscal year end

3/31

Latest filing

Interim Financial Report (Sep 30, 2023)

Appili Therapeutics Inc. leadership

• Don Cilla — CEO, President
• Theresa Matkovits — Lead Director
• Kenneth Howling — Acting CFO
• Jenna McNeil — Corp. Commun.

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with A